|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Early markers of anthracycline сardiotoxicity in treatment of patients with breast cancerстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 20 июня 2024 г.
- Авторы: Vladimirova Liubov Yu, Kit Oleg I., Guskova Nailya, Tikhanovskaya Natalya Mikhailovna, Sycheva Elena A., Nozdricheva Anastasia, Abakumova Svetlana V., Abramova Natalya A., Storozhakova Anna E., Popova Irina L., Ryadinskaya Ludmila A., Lyanova Aza A., Novoselova Kristina A., Lisunova Zinaida P., Avanesova Kristina, Zekhtser Ineya I., Belgova Svetlana V., Zakharchenko Viktoria, Tselishcheva Irina V., Torpudzhyan Izabella
- Журнал: Journal of Clinical Oncology
- Том: 36
- Номер: 15_suppl
- Год издания: 2018
- Издательство: American Society of Clinical Oncology
- Местоположение издательства: United States
- Первая страница: e14506
- Последняя страница: e14506
- DOI: 10.1200/jco.2018.36.15_suppl.e14506
- Аннотация: Background: The purpose of the study was to assess changes in biochemical markers of cardiotoxicity in anthracycline chemotherapy for breast cancer. Methods: The study included 30 pts (32-72 years, 50%<50 years) with stage II-III breast cancer (BC) receiving 4 cycles of anthracycline (AC) chemotherapy (CT). N-terminal pro-brain natriuretic peptide (NT-proBNP), troponin I (TI), creatine kinase (CK), creatinine and urea were determined (Vitros 5600, USA) in the blood serum before AC administration and on days 2 and 5 after it. The results were compared with electrocardiography and echocardiography (EchoCG) data. The data were processed using the Statistica 6.0 program. Results: No clinical or instrumental data on an acute myocardial infarction were registered. NT-proBNP˃64.0 pg/mL was considered as high. Before treatment, 15 (50%) pts showed increased NT-proBNP (on average 144.3±38.8 pg/mL), which correlated with EchoCG results and indicated initial cardiovascular pathology. The initial level of NT-proBNP in other pts was 48.2±14.7 pg/mL. Correlation between the age and NT-proBNP was not found (p > 0.05). Day 2, NT-proBNP increased by 2.6 times (p < 0.01) in 26 (86.7%) pts: 15 (50.0%) with initially high levels and 12 (40.0%) with initially normal ones. Day 5, NT-proBNP increased in 7 (23.3%) pts and decreased in 6 (20.0%). NT-proBNP levels restored to initial values by the 4th CT cycle. The changes after the 1st AC injection and on days 2 and 5 were similar in direction. TI and CK did not change at all stages even in pts with high NT-proBNP, indicating the development of reversible cardiotoxic effect. Levels of creatinine and urea were within the reference range which excluded their impact on NT-proBNP. Conclusions: NT-proBNP is bound to be the most sensitive marker of cardiotoxicity and could serve as an earlier marker in patients with breast cancer undergone chemotherapy with anthracyclines.
- Добавил в систему: Владимирова Любовь Юрьевна